Why Test for Proportional Hazards?
作者信息
Stensrud Mats J, Hernán Miguel A
机构信息
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Biostatistics, Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway.
出版信息
JAMA. 2020 Apr 14;323(14):1401-1402. doi: 10.1001/jama.2020.1267.
Abstract
摘要
相似文献
1
Why Test for Proportional Hazards?为什么要检验比例风险？
JAMA. 2020 Apr 14;323(14):1401-1402. doi: 10.1001/jama.2020.1267.
2
A MCP-Mod approach to designing and analyzing survival trials with potential non-proportional hazards.MCP-Mod 方法在具有潜在非比例风险的生存试验设计和分析中的应用。
Pharm Stat. 2022 Nov;21(6):1294-1308. doi: 10.1002/pst.2241. Epub 2022 Jun 23.
3
Sequential tests for non-proportional hazards data.非比例风险数据的序贯检验。
Lifetime Data Anal. 2017 Jul;23(3):339-352. doi: 10.1007/s10985-016-9360-5. Epub 2016 Mar 11.
4
A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.比例风险治愈模型下加权对数秩检验的一种新型样本量公式。
Pharm Stat. 2017 Jan;16(1):87-94. doi: 10.1002/pst.1790. Epub 2016 Nov 8.
5
A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.不同人群水平汇总指标在时间事件结局随机试验中的比较，重点关注非劣效性试验。
Clin Trials. 2023 Dec;20(6):594-602. doi: 10.1177/17407745231181907. Epub 2023 Jun 20.
6
Are restricted mean survival time methods especially useful for noninferiority trials?限制平均生存时间法是否特别适用于非劣效性试验？
Clin Trials. 2021 Apr;18(2):188-196. doi: 10.1177/1740774520976576. Epub 2021 Feb 24.
7
Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.在可能预期治疗效果存在非比例风险的临床试验设计中增强对数秩检验。
BMC Med Res Methodol. 2016 Feb 11;16:16. doi: 10.1186/s12874-016-0110-x.
8
An empirical comparison of statistical tests for assessing the proportional hazards assumption of Cox's model.评估Cox模型比例风险假设的统计检验的实证比较。
Stat Med. 1997 Mar 30;16(6):611-26. doi: 10.1002/(sici)1097-0258(19970330)16:6<611::aid-sim437>3.0.co;2-t.
9
Dealing with the proportional hazards assumption when using the proportional hazards model with a single independent variable.在使用具有单个自变量的比例风险模型时处理比例风险假设。
Jpn J Clin Oncol. 1989 Sep;19(3):195-201.
10
Optimality of testing procedures for survival data in the nonproportional hazards setting.非比例风险生存数据检验方法的最优性。
Biometrics. 2021 Jun;77(2):587-598. doi: 10.1111/biom.13315. Epub 2020 Jun 24.
引用本文的文献
1
Associations of serum iron and its status change with mortality risk: prospective findings from the MJ cohort.血清铁及其状态变化与死亡风险的关联：MJ队列研究的前瞻性结果
Eur J Epidemiol. 2025 Sep 1. doi: 10.1007/s10654-025-01295-w.
2
Comparative performance of multiple inflammatory indices across different stages of cardiovascular-kidney-metabolism syndrome: A Multi-Cohort Study.心血管-肾脏-代谢综合征不同阶段多种炎症指标的比较性能：一项多队列研究。
Endocrine. 2025 Aug 18. doi: 10.1007/s12020-025-04390-w.
3
Prediagnostic self-rated health and survival in women diagnosed with cancer in the Norwegian Women and Health Study: a prospective cohort study.挪威女性与健康研究中癌症确诊女性的诊断前自评健康状况与生存情况：一项前瞻性队列研究
BMJ Open. 2025 Aug 13;15(8):e099992. doi: 10.1136/bmjopen-2025-099992.
4
The Effect of Incarceration on Mortality.监禁对死亡率的影响。
Rev Econ Stat. 2024 Jul;106(4):956-973. doi: 10.1162/rest_a_01224. Epub 2024 Jul 8.
5
Use of Systemic Glucocorticoids and Risk of Prostate Adenocarcinoma: Evidence From a Danish Population-Based Case-Control Study.全身糖皮质激素的使用与前列腺腺癌风险：来自丹麦一项基于人群的病例对照研究的证据。
Cancer Med. 2025 Aug;14(15):e71110. doi: 10.1002/cam4.71110.
6
Hepatic artery infusion chemotherapy combined with lenvatinib and PD-1 inhibitors in the treatment of intermediate and advanced unresectable hepatocellular carcinoma.肝动脉灌注化疗联合乐伐替尼及PD-1抑制剂治疗中晚期不可切除肝细胞癌
Oncol Lett. 2025 Jul 9;30(3):437. doi: 10.3892/ol.2025.15183. eCollection 2025 Sep.
7
Analysis of follow-up data in large biobank cohorts: a review of methodology.大型生物样本库队列中的随访数据分析：方法学综述
Front Genet. 2025 Jun 25;16:1534726. doi: 10.3389/fgene.2025.1534726. eCollection 2025.
8
Long-term implant survival in delayed breast reconstruction.延迟乳房重建中长期植入物的存活率
BJS Open. 2025 Jul 1;9(4). doi: 10.1093/bjsopen/zraf071.
9
Revisiting the hazards of hazard ratios through simulations and case studies.通过模拟和案例研究重新审视风险比的危害。
Eur J Epidemiol. 2025 Jul 3. doi: 10.1007/s10654-025-01245-6.
10
Self-reported pain is associated with a poorer long-term prognosis in patients with myocardial infarction: A SWEDEHEART study.自我报告的疼痛与心肌梗死患者较差的长期预后相关：一项瑞典心脏注册研究。
Int J Cardiol Heart Vasc. 2025 Jun 18;59:101719. doi: 10.1016/j.ijcha.2025.101719. eCollection 2025 Aug.
本文引用的文献
1
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.使用受限平均生存时间替代风险比来解释癌症临床试验结果的可解释性。
JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797.
2
Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial.结肠镜筛查对结直肠癌发病率和死亡率的影响：一项随机临床试验。
JAMA. 2014 Aug 13;312(6):606-15. doi: 10.1001/jama.2014.8266.
3
The hazards of hazard ratios.风险比的危害
Epidemiology. 2010 Jan;21(1):13-5. doi: 10.1097/EDE.0b013e3181c1ea43.
4
Estrogen plus progestin and the risk of coronary heart disease.雌激素加孕激素与冠心病风险
N Engl J Med. 2003 Aug 7;349(6):523-34. doi: 10.1056/NEJMoa030808.
5
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.健康绝经后妇女使用雌激素加孕激素的风险与益处：妇女健康倡议随机对照试验的主要结果
JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321.
6
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.洛伐他汀对胆固醇水平正常的男性和女性急性冠脉事件的一级预防：空军/德州冠状动脉粥样硬化预防研究（AFCAPS/TexCAPS）的结果
JAMA. 1998 May 27;279(20):1615-22. doi: 10.1001/jama.279.20.1615.
Zotero 插件